Would you use AR-V7 testing to decide second-line androgen receptor-axis-targeted therapy vs chemotherapy for patients who with metastatic castration-resistant prostate cancer?
If yes, what factors push you to test for AR-V7 or would you test all patients in this clinical scenario?